Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography
US11350901B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 27, 2018 |
| Grant date | Jun 7, 2022 |
| Priority date | — |
| Expiry date | Jan 3, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG06V2201/031
- WIPO fieldComputer technology
- WIPO sectorElectrical engineering
Abstract
Embodiments generate an early stage NSCLC recurrence prognosis, and predict added benefit of adjuvant chemotherapy. Embodiments include processors configured to access a radiological image of a region of tissue demonstrating early stage NSCLC; segment a tumor represented in the radiological image; define a peritumoral region based on a morphological dilation of a boundary of the tumor; extract a radiomic signature that includes a set of tumoral radiomic features extracted from the tumoral region, and a set of peritumoral radiomic features extracted from the peritumoral region, based on a continuous time to event data; compute a radiomic score based on the radiomic signature; compute a probability of added benefit of adjuvant chemotherapy based on the radiomic score; and generate an NSCLC recurrence prognosis based on the radiomic score. Embodiments may display the radiomic score, or generate a personalized treatment plan based on the radiomic score.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.